FDA Peptide Review
The Food and Drug Administration will convene an expert panel to evaluate whether restrictions on a broad category of peptide compounds should be eased, responding to pressure from Health Secretary Robert F. Kennedy Jr. And aligned public health figures who have promoted the substances as part of the MAHA platform.
Peptides currently sit on the FDA's list of bulk drug substances that may not be used in compounding, meaning licensed pharmacies and telehealth providers are prohibited from preparing and dispensing them outside of approved drug products. Any regulatory reclassification would open a significant new product category for compounders and the platforms that distribute their formulations.
Hims & Hers, the direct-to-consumer telehealth company, has publicly applauded the FDA's move, framing it as a step toward regulatory clarity on peptide therapy. The company's stock extended gains on the news, according to Yahoo Finance and MarketWatch, though no specific price levels appear in the source reporting. Hims & Hers has been navigating a transition in its GLP-1 business following earlier FDA decisions on compounded semaglutide, and a permissive peptide ruling would diversify its compounding revenue base.
The FDA has not announced a timeline for the panel's conclusions or any subsequent rulemaking. Critics of the move note that the peptides in question lack the clinical trial data ordinarily required for broader therapeutic use, and the agency's own prior restrictions reflected those evidentiary gaps.
